Aligos Therapeutics, Inc.
ALGS · XNASCIK 1799448fmd_1Z3W9KKZQ7JXSYQRX0656S8G7VManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2019 to Sep 30, 2026, 29 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Total revenues | – | 0 | 0 | 0 | 6 | 4 | 2 |
| Net interest income | – | – | – | 2 | 4 | 2 | 2 |
| Research and development | 44 | 80 | 104 | 85 | 73 | 70 | 69 |
| Total operating expenses | 54 | 98 | 133 | 111 | 104 | 93 | 90 |
| Operating income | (54) | (98) | (128) | (98) | (88) | (89) | (88) |
| Income before taxes | (52) | (108) | (128) | (96) | (87) | (131) | (24) |
| Income tax expense | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Net income from continuing operations | (52) | (109) | (128) | (96) | (88) | (131) | (24) |
| Net income | (52) | (109) | (128) | (96) | (88) | (131) | (24) |